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Gangliosides GM1 is a good marker of membrane microdomains (lipid rafts) with important function in cellular activation
processes. In this study we found that GM1 expression on CD4+ T cells and memory T cells (CD45RO/CD4) were dramatic
increased after stimulation with phytohaemagglutinin in vitro. Next, we examined the GM1 expression on peripheral blood CD4+
T cells and CD8+ T cells from 44 patients with SLE and 28 healthy controls by ﬂow cytometry. GM1 expression was further
analyzed with serum soluble CD30 (sCD30), IL-10, TNF-alpha and clinical parameters. The mean ﬂuorescence intensity of GM1
on CD4+ T cells from patients with SLE was signiﬁcantly higher than those from healthy controls, but not on CD8+ T cells.
Increased expression of GM1 was more marked on CD4+/CD45RO+ memory T cells from active SLE patients. Patients with
SLE showed signiﬁcantly elevated serum sCD30 and IL-10, but not TNF-alpha levels. In addition, we found that enhanced GM1
expression on CD4+ T cells from patients with SLE positively correlated with high serum levels of sCD30 and IgG as well as disease
activity (SLEDAI scores). Our data suggested the potential role of aberrant lipid raft/GM1 on CD4+ T cells and sCD30 in the
pathogenesis of SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a multisystem,
autoimmune, connective-tissue disorder in which organs
and cells undergo damage mediated by tissue-binding
autoantibodies and immune complexes [1]. T cells from
SLE patients are known to provide help to B cells to
produce autoantibodies and numerous abnormalities of
T cells including aberrancies of proliferation, cell death,
signaling, and cytokines production have been described in
the pathogenesis of SLE [2, 3].
Lipid rafts are liquid ordered sphingolipid and
cholesterol-enriched membrane domains, functioning
in cellular processes, especially in signal transduction
through recruiting signaling and stimulatory proteins
[4], and play a critical role in T lymphocytes activation,
particularly in signaling from the T-cell antigen receptor
(TCR) and in localization and function of proteins residing
proximal to the receptor [4–7]. Ganglioside GM1, a major
constituent of cellular membranes acting as a rigid barrier to
the extracellular environment, is one of the important com-
ponent of lipid raft [4]. Elevated GM1 have been observed in
activatedT-cells[8].HighlevelsofGM1andcholesterolhave
been found in peripheral blood T cells from SLE patients,
which was only measured in whole negatively selected T cells
population by confocal microscopy study [9]. However, the
levels of GM1 in T cell subgroups such as CD4+ helper T
cells and CD8+ cytotoxic T cells are largely unknown.2 Journal of Biomedicine and Biotechnology
CD30, a 120-kDa type I transmembrane glycoprotein,
is normally found on a subset of activated T cells, which
are involved in the induction of cell proliferation and
initiation of apoptosis [10]. The soluble form of CD30
(sCD30)isreleasedfromactivatedTcellsthroughproteolytic
cleavage. Elevated serum levels of sCD30 have been found in
Hodgkin’s disease, anaplastic large cell lymphoma, infectious
a n da l l e r g i cd i s e a s e sa sw e l la ss o m ea u t o i m m u n ed i s e a s e s ,
such as SLE and rheumatoid arthritis [11, 12]. However, its
relationship with the membrane raft GM1 and cytokines in
SLE has not been deﬁned. To analyze lipid raft expression on
each subgroup T cells in SLE and its relation to abnormal T
cell activation and cytokine production, we quantiﬁed GM1
expression on both peripheral CD4+ and CD8+ T cells from
the SLE patients via ﬂow cytometry and compared it to the
serum levels of sCD30 and Th1/Th2 balance of cytokines as
well as clinical parameters. We found that GM1 expression
was increased on CD4+ T cells and there were signiﬁcant
correlationsbetweenGM1expressionandsCD30anddisease
activity in SLE.
2.MaterialsandMethods
2.1. Patients and Healthy Controls. Forty-four consecutive
patients fulﬁlling the revised American College of Rheuma-
tology (ACR) criteria for the diagnosis of SLE [13]w e r e
recruited for this study. Twenty-eight age-matched healthy
volunteers served as controls. Disease activity was scored
and the SLE Disease Activity Index (SLEDAI) was calculated
based on previous report [14]. Patients were divided into
subgroups according to clinical disease activity (i.e., active
≥10 and inactive <10 by SLEDAI) and serum IgG level (high
IgG >15g/L), respectively. Our study included 21 active SLE
patients, 23 inactive patients with SLEDAI ranging from one
to 20, and 28 healthy control volunteers. Written informed
consent was obtained from all participating patients and
volunteers. Complete blood cell count, serum complement,
serum IgG, antinuclear and anti-DNA antibodies were
measured in all patients.
2.2. FACS Analysis. Surface expression of CD4, CD8,
CD45RO, and GM1 were analyzed from the peripheral
blood cells by double or triple-staining using FITC-, PE-,
APC-labeled mAbs in the relevant combinations. Two color
immunoﬂuorescence analysis was performed on a FACScan
ﬂow cytometer (BD Biosciences, San Jose, CA), using
CellQuest Pro (BD Biosciences) software. Detection of GM1
expression was performed by staining peripheral blood with
PE-conjugated anti-CD4 or CD8 antibodies (eBioscience
Co. Ltd, USA) and FITC-conjugated cholera toxin-B (CTB,
Sigma-Aldrich, USA) as described previously [15]. For triple
staining, cells were ﬁrst analyzed by APC-conjugated CD4,
then GM1 expression was detected with PE anti-CD45RO
antibody and FITC cholera toxin-B.
2.3. Expression of GM1 on PHA-Activated T Cells during
Culture. Mononuclear cells were isolated from heparinized
peripheral blood from the healthy subjects by density-
gradient centrifugation on Ficoll-Hypaque (Pharmacia,
Uppsala, Sweden). The cells were then stimulated with
1μg/ml of PHA (Boehringer Mannheim, Germany) and
maintained in RPMI 1640 medium supplemented with
10% FCS (Upstate Biotechnology, Inc., UBI, Lake Placid,
NY), 2mM L-glutamine, penicillin, and streptomycin in
the presence of 2nM recombinant IL-2 (Shionogi Co. Ltd.,
Osaka, Japan) for 2 weeks. To analyze surface expression of
ganglioside GM1 and CD45RO on CD4+ T cells, cells were
stained with FITC-conjugated CTB (Sigma-Aldrich), PE-
conjugated anti-CD45RO and APC-conjugated anti-CD4
mAbs (BD Bioscience) on ice for 30 minutes, respectively,
and analyzed with a FACSan. Data were analyzed using
CellQuest software (Becton Dickinson).
2.4. ELISA. The serum levels of sCD30, IL-10, and TNF-
α were measured by an enzyme-linked immunosorbent
assay (ELISA) commercial kit (R&D Co. Ltd. USA) [16,
17]. The serum IgG of the SLE patients was detected by
immunoturbidimetric assay (Orion Diagnostica Oy Co. Ltd.
Finland). The results were subjected to the independent
samplet-test,correlationtests,andbivariateanalysis.Avalue
of P<. 05 was considered to be statistically signiﬁcant.
3. Results
3.1. GM1 Expressions on CD4+ T Cells and Memory T Cells
(CD45RO/CD4) Were Dramaticly Increased after Stimulation
with PHA In Vitro. CTB binds the raft-associated GM1,
previouslyshowntobeareliablemarkerfordetectionoflipid
raft domains [18]. First, we analyzed the rafts on mitogen-
stimulated T cells in vitro through FACS. GM1 surface
expression with ﬂuorescent-labeled CTB was determined on
days 0, 2, 5, 8, 11 and 14 after stimulation with 1μg/ml of
PHA. The mean ﬂuorescence intensity (MFI) of memory T
cells (CD45RO/CD4) were dramatically increased in time-
dependent manner after stimulation (Figures 1(a) and 1(b))
aswellasCD4+Tcells(Figure1(c)).Thesedataindicatethat
cellular membrane adopts an increased lipid raft structure
upon mitogenic stimulation in CD4+ T cells and CD4+
memory T cells.
3.2. Elevated Expression of GM1 Was Presented on CD4+ T
Cells, Not on CD8+ T Cells from SLE Patient Peripheral Blood.
Next, we examined the expression of GM1 on peripheral
blood CD4+ T cells and CD8+ T cells from 44 patients
with SLE and 28 healthy controls by ﬂow cytometry. The
MFI of GM1 on peripheral CD4+ T cells from patients with
SLE were signiﬁcantly stronger than those from the healthy
controls (P<. 01) (Figure 2(a)). Although the increase of
CD4+ T cells expressing GM1 was small, the substantial
change in GM1 expression as measured by MFI suggests
that increased GM1 expression aﬀects a high proportion of
lupus CD4+ T cells. When we divided SLE patients into
active group (n = 21) and inactive group (n = 23)
according to SLEDAI scores (active ≥10, inactive <10), MFI
of GM1 in both groups are higher than those of healthyJournal of Biomedicine and Biotechnology 3
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Figure 1: Time kinetics of GM1 expressions on PHA-activated T cells. Peripheral mononuclear cells were stimulated with 1μg/ml of PHA
and maintained with IL-2-containing medium for two weeks. GM1 expression on memory T cells were detected with FITC-CTB and PE-
CD45RO antibody on days 0, 2, 5, 8, 11 and 14 after stimulation (a). The mean ﬂuorescence intensity (MFI) of GM1 were measured on
CD45RO+/CD4+ memory T cells (b) and CD4+ T cells (c). Each experiment was done in triplicate. Error bars represent S.E.M.
controls. Although the diﬀerence was not signiﬁcant, MFI of
GM1 in active group is higher than that in inactive group
(Figure 2(a)). When we divided SLE patients into high IgG
group (n = 24) and normal IgG group (n = 20) according
to serum IgG level (>15g/L), MFI of GM1 on CD4+ T cells
from high IgG group was statistically higher than that from
normal IgG group (P<. 05) (Figure 2(a)). In contrast to
CD4+ T cells, no signiﬁcant diﬀerence in expression of GM1
on CD8+ T cells was observed between SLE patients and the
healthy controls (Figure 2(b)).
Further, we analyzed GM1 expression on
CD45RO+/CD4+ memory T cells from 11 of inactive
SLE, 14 of active SLE patients and 23 healthy controls
by triple staining (Figures 2(c)–2(e)). Figure 2(c) shows
that there are no signiﬁcant diﬀerences in percentage of
CD4 T cells among inactive SLE (42.2 ± 3.04), active SLE
(38.8 ± 2.64), and healthy controls (46.9 ± 2.17). We did
not found the signiﬁcant diﬀerence of the MFI of GM1 on
CD45RO+/CD4+ memory T cells among each group (data
not shown). However, when we determined the cell with
morethan10inMFIofGM1ashighGM1cells(Figure2(d)),
percent of high GM1 cells among CD45RO+/CD4+ memory
Tcellswassigniﬁcantlyincreasedin SLEpatients (1.00±0.07
and 1.35 ± 0.12 for inactive and active SLE, resp.) compared
with healthy controls (0.69 ± 0.03) (Figure 2(e)). Although
the change in the percentage of high GM1 cells was small,
this represented a twofold increase compared with those
from healthy individuals. Moreover, percent of high GM1
cells in active SLE is signiﬁcantly higher than that in inactive
SLE (Figure 2(e)). The elevation in high GM1 cells of
memory T cells was dependent of lupus disease activity
status.
3.3. The Serum Levels of sCD30 and IL-10 Were Signiﬁcantly
Increased in the SLE Patients, But TNF-α Was Not. The
serum levels of sCD30 were averaged 149.74 ± 63.85ng/ml
in the SLE patients (149.25 ± 66.83ng/ml in active patients,4 Journal of Biomedicine and Biotechnology
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Figure 2: Lipid raft/GM1 expression on CD4+ T cells (a) and CD8+ T cells (b). SLE patients were divided into subgroups; active SLE
group (n = 21) versus inactive SLE group (n = 23) according to SLEDAI scores, and high IgG group (n = 24) versus normal IgG group
(n = 20) according to serum IgG level. ∗Statistically signiﬁcant diﬀerences compared to the healthy (∗P<. 05,
∗∗P <. 01). #Statistically
signiﬁcant diﬀerences between subgroup with high IgG and normal IgG. (P<. 01) (Two-tailed unpaired Student’s t-test). (c) Percentage
of CD4-positive T cells among healthy controls (n = 23), inactive (n = 11) and active SLE patients (n = 13) were 46.9+2.17, 42.2+3.04
and 38.8+2.64, respectively. (d) GM1 expression on CD45RO+/CD4+ memory T cells by triple staining. Cells were ﬁrst gated by CD4-APC,
then analyzed with PE-CD45RO antibody and FITC-GM1. Cells with more than 10 in MFI of GM1 were determined as high GM1 cells.
(e) Percent of high GM1-expessing CD45RO+/CD4+ memory T cells among normal controls, inactive and active SLE patients (0.69 ±0.03,
1.00 ±0.07, 1.35 ±0.12, resp.).
∗∗P<. 01
150.3 ± 62.65ng/ml in inactive patients), and were averaged
79.49 ± 22.93ng/ml in the healthy controls, showing a
signiﬁcant increase of serum sCD30 in the SLE patients,
compared to healthy controls (P<. 01), although there
was not diﬀerence between SLE active and inactive groups
(Figure 3(a)). Levels of IL-10 were 94.6 ± 57.93pg/ml in the
SLE patients (89.07±46.44pg/ml in active patients, 100.86±
69.9pg/mlininactivepatients)and44.96±33.30pg/mlinthe
healthy controls. There were statistical diﬀerences between
theSLEpatientsandhealthycontrols(P<. 05)(Figure3(b)).
TNF-α were 18.62 ± 9.57pg/ml in the SLE patients (19.35 ±
9.15pg/ml in the active patients, 17.80 ± 10.20pg/ml in the
inactive patients) and 16.91 ± 13.18pg/ml in the healthy
controls. There were no statistical diﬀerences in the levels
of TNF-α between the SLE patients and the healthy controls
(Figure 3(c)).
3.4. The Correlation among GM1 Expression on CD4+ T
Cells, SLEDAI Scores, sCD30, IgG Levels and Other Clinic
Parameters in the SLE Patients. Analyzing the correlations
amongtheSLEpatients,wefoundthattherewasasigniﬁcant
correlationbetweenGM1expressiononCD4+Tcells(MFI),
SLEDAI scores(r = 0.556, P<. 005), plasma level of SCD30
(r = 0.51, P<. 005), and serum IgG levels (r = 0.56,
P<. 005) in the SLE patients. In particular, the correlation
between MFI of GM1 on CD4+ T cells and SLEDAI was
much stronger in active SLE group (r = 0.813, P<. 001)
than those in inactive group (r = 0.668, P<. 005). No
Table 1: Correlations among the levels of sCD30 IgG, GM1
expression, and SLEDAI scores (∗P<. 005).
GM1 SLEDAI sCD30 IgG
GM1 1
SLEDAI 0.56
∗ 1
SCD30 0.51
∗ NS 1
IgG 0.52
∗ NS 0.56
∗ 1
signiﬁcant correlation was found between GM1 and IL-10,
ANA titer, C3, and other clinic parameters (data not shown).
Furthermore, we found that the plasma level of SCD30 was
positively correlated with the IgG level (Table 1). But no
statistical diﬀerence was observed between sCD30 levels and
otherparameters(datanotshown).Inaddition,nostatistical
diﬀerence was observed between expression of GM1 on
CD45RO+/CD4+ memory T cells and above parameters in
patients with SLE.
4. Discussion
T-cell abnormalities and aberrant T helper cytokine proﬁles
have been implicated in pathogenic process of SLE. Previous
studies have demonstrated that negative selected peripheral
bloodTcellsfromtheSLEpatientshavehigherlevelsofGM1
[9]. In this study, we quantitatively measured membrane6 Journal of Biomedicine and Biotechnology
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Figure 3: Serum levels of sCD30 (a), IL-10 (b) and TNF-α(c) in the SLE group, in the healthy controls, in the subgroups with active and
inactive SLE. ∗Statistically signiﬁcant diﬀerences between the healthy controls and the marked SLE group & subgroups (P<. 01).
GM1 on peripheral blood CD4+ and CD8+ T cells, respec-
tively, and found that CD4+ T cells expressed elevated GM1,
but CD8+ T cells did not, in SLE patients. In addition, GM1
expressions on memory T cells (CD45RO/CD4) and CD4+
T cells were dramaticly increased after PHA stimulation
in vitro. Furthermore, number of GM1-highly expressing
CD45RO+CD4+memoryTcellsweresigniﬁcantlyincreased
inSLEpatientscomparedwithhealthycontrols(Figure2(e)).
These data may indicate that cellular membrane adopts an
increased lipid raft structure upon mitogenic stimulation
and CD4+ T cells in SLE patients are continuously activated
by autoantigens in vivo. It has been reported that CD8+ T
cells in SLE are impaired and CD8+ T cells do not require
the polarization of lipid rafts for activation and proliferation
[19]. However, activated CD4+ helper T cells produce more
cytokines and help B cells secrete autoantibodies that form
immune complexes, resulting in subsequent inﬂammation
and organ damage [20]. Additionally, we found that there
wasapositivecorrelationbetweenGM1expressiononCD4+
T cells (MFI) and SLEDAI scores (r = 0.556, P<. 005)Journal of Biomedicine and Biotechnology 7
as well as serum IgG levels (r = 0.56, P<. 005) in
SLE group, suggesting a possible role of lipid raft GM1 in
pathogenesis of SLE. It has been documented that SLE T cells
possess dysregulated activity of multiple protein tyrosine
kinases [9, 20, 21]. We hypothesize that high level of GM1
on CD4+ T cells may induce changes in membrane density
and segmentation impacting on signal strength. Previously,
we reported that lipid rafts function as scaﬀolds for TCR
signals by recruiting TCR, ZAP-70 and PKC-θ into rafts
using membrane sphingomyelin knock down Jurkat cells
[9]. These modulations may also facilitate that signaling,
and the stimulatory proteins are recruited to or modiﬁed in
lipidrafts,subsequentlyconveyaberrantintracellularsignals,
resulting in abnormal CD4+ T cell function [5]. These
aberrances lead to the survival of autoimmune B clones and
overproduction of antibodies, eventually contribute to the
development of SLE [22].
Although CD30 originally described as a marker on
Reed-Sternberg cells in Hodgkin lymphoma [10], CD30 can
be found on various populations of T cells (both CD4+
and CD8+ cells), especially helper T cells which produce
cytokines. The extracellular portion of CD30 is proteolyt-
ically cleaved from CD30+ cells, possibly on activation by
CD30L, to produce a soluble form of the molecule (sCD30)
detectable in serum [23]. The sCD30 belongs to the TNF
superfamily and is important in the interaction and the
activation of T and B cells. High levels of sCD30 have been
seen in the cases of T helper immunodeﬁciency diseases,
allergic diseases, the severe infections and autoimmune
disease [23], and sCD30 has been proposed as a marker for
a Th2-oriented immune response [12, 24]. Cifersk´ ae ta l .
reported that there was a signiﬁcant diﬀerences of sCD30 at
serum levels between the SLE patients and the controls [11].
We also found signiﬁcant diﬀerences of serum sCD30 level
between the SLE patients and healthy controls. Moreover,
we found that there was a positive correlation between GM1
expression on CD4+ T cells (MFI) and serum level of SCD30
(r = 0.51, P<. 005). A Triton X-100-based method for lipid
raftisolationrevealedthatCD30waspartiallypresentinlipid
rafts [25]. Additionally, Bastian von Tresckow et al. found
that cellular lipid raft such as cholesterol level regulate CD30
shedding in human Hodgkin lymphoma- and non-Hodgkin
lymphoma derived cell line [25], implying the potential
relationship between lipid raft and sCD30. Recently, sCD30
has been shown to be important for the regulation of the
immune system in vivo and in vitro, and it is likely to play
a regulatory role in the Th1/Th2 type immune response
[26, 27]. Increased serum levels of sCD30 in autoimmune
diseasedemonstratedthattheaberrantlipidraftisconnected
to an increased secretion of sCD30.
We further measured the TNF-α and IL-10 which
respectively indicate Th1 and Th2 activation [2, 3, 26]. We
found that the levels of IL-10 were signiﬁcantly higher in
SLE than those in healthy controls, however no signiﬁcant
diﬀerence of TNF-α was observed. Although the role of IL-
10 in SLE pathogenesis has not been completely elucidated,
IL-10 is considered a regulatory Th2 cytokine, and it causes
activation, diﬀerentiation, and antibody production in B-
cells [3]. In addition, current studies reveal the existence of
a subset of B cells with regulatory capacities. This regula-
tory subset is characterized by the secretion of IL-10 and
transforming growth factor-β (TGF-β) and has been shown
to be involved in the pathogenesis of autoimmune diseases
[28]. However, we did not found the positive correlation
between IL-10 and sCD30, as well as other parameters. Our
data suggest that SLE IL-10 is complex and has pleiotropic
eﬀects in immunoregulation and inﬂammation.
Taken together, we have found an aberrant GM1 expres-
sion on CD4+ T cells and signiﬁcant correlations between
GM1 expression and sCD30 and disease activity in SLE,
indicating that lipid raft may become a direct target for
modulation of the immune system. Additional research is
needed to better understand the biologic basis of this eﬀect.
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